Applying the Fragility Index to Randomized Controlled Trials Evaluating Total Neoadjuvant Therapy for Rectal Cancer: A Methodological Survey

Level I evidence, the highest quality evidence, comes from randomized controlled trials (RCTs).[1]The impact of level I evidence (i.e., RCTs) on clinical practice is largely determined by the presence of statistically significant findings, or lack thereof. This is most referenced in terms of the p-value. A cut-off value of 0.05 or less for p-values denotes a treatment effect that is unlikely to be due to chance alone.[2] However, the American Statistical Association (ASA) has criticized the use of the p-value alone due to the arbitrary cut-off value and the lack of consideration for the treatment effect size and the precision of the result.

Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Tyler McKechnie, Kelly Brennan, Cagla Eskicioglu, Ameer Farooq, Sunil Patel Tags: Review Article Source Type: research